US industry holds aim on ''Tax on medical progress''
This article was originally published in Clinica
Executive Summary
Undaunted by last autumn’s independent analyst report that cast doubt on US medical device manufacturers‘ claims that the 2.3% device sales tax is seriously damaging to the local industry, AdvaMed has returned fire.